DNER and acute myeloid leukemia: This class of inhibitors has already exhibited effective anti-cancer activities in preclinical models of many cancer types [23], including breast cancer [15], PCa [11, 24], acute myeloid leukemia [13], and show promise in other cancer types with a reliance on BET family proteins, such as squamous cell carcinoma [25].